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"If it were not for the great variability among individuals,
medicine might as well be a science, not an art." Sir
William Osler, 1892
The renowned Canadian physician and McGill
alumnus got it right. Much of medical science over the
past century has documented intra-and inter-individual
variability, however the rationale for this variability is
not well understood and not often applied in clinical
practice. Indeed most therapeutic strategies rely on data
derived from randomized clinical trials (RCTs) and
large observational studies, and applied to the so-called
"statistically average" patient. Although medicine will
continue to remain very much an art, just over a
hundred years after Osler's observation, we are
beginning to understand the factors driving inter-
individual variability. Armed with details of individual
variation, physicians could divide patients into
subgroups and predict which are likely to have an
aggressive or indolent form of a disease and which
would respond to one drug rather than another. 
The emergence and continued growth of personalized
medicine will catalyze fundamental changes at many
different levels in the future of health care and health
systems. The objective of this special focus article is to
describe the role and increasing importance of
personalized medicine in health care, as well as discuss
some of the ongoing challenges for integrating
personalized medicine into contemporary medicine. 
WHAT IS PERSONALIZED MEDICINE?
A personalized medicine approach to providing health
services involves integrating genomics technologies
and advances with clinical and family histories in order
to more coherently tailor therapeutics to individual
patients. A key component of personalized medicine is
translating the science of pharmacogenomics into
clinical practice. Pharmacogenomics is increasingly
seen as holding the potential for tailoring prescriptions
to defined sub-populations and possibly individuals,
based upon genetic make-up, and therefore, ultimately
improving the effectiveness and safety of drugs. 
A BRIEF HISTORICAL OVERVIEW OF
PHARMACOGENETICS AND
PHARMACOGENOMICS
The capacity for genetic differences to affect response
to the biochemical environment has been known for
over 100 years. Historically, one of the first indications
of genetic polymorphism in drug metabolism was
suggested by studies on alkaptonuria in 1902 (1).
Alkaptonuria is a disorder in which the enzyme
homogentisate oxidase does not correctly process its
intended target substrate, homogentisic acid, leading to
a build up of that substrate. Alkaptonuria is usually
asymptomatic, but can lead to arthritis. 
A curious observation of hemolysis among African-
American soldiers in response to taking the antimalarial
drug primaquine provided evidence of genetic variation
in response to drug ingestion when further studies
demonstrated that this primaquine - induced hemolysis
was due to a genetic deficiency of the enzyme glucose
-6-phosphate dehydrogenase (G-6-PD) (2).  The
significance of pharmacogenetics to the clinical care of
patients was shown by Kalow and Gunn who observed
an excessive neuromuscular blockade and longer-
lasting apnea in some patients who had been
administered the neuromuscular blocking agent,
succinylcholine, as part of undergoing
electroconvulsive therapy (3). These and other
observations established the early foundation of the
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field of pharmacogenetics. 
The more recently coined term, "pharmacogenomics"
is more encompassing describing the impact of genomic
information on the drug discovery process. Therefore,
pharmacogenomics includes identifying candidate
genes and polymorphisms, correlation of
polymorphisms with therapies, prediction of drug
response and clinical outcomes, reduction in adverse
events, and selection and dosing of drugs based on
genotype (4). Thus, the prediction of polymorphisms
has implications for reducing adverse events, improving
the design of rational drug development, and eventual
drug prescription. 
Some of the anticipated long-term benefits of
pharmacogenomics include the potential for
"personalized" or "customized" prescriptions, improved
patient compliance, reduction or elimination of certain
adverse events and the reduction in cost of disease
management. The potential applications for genotyping
for pharmacogenomics purposes are diverse and are
primarily driven by three requirements (4-7): first, the
need to determine the safety and efficacy of an
experimental new drug prior to approval; second, the
need to establish an individual's genetic predisposition
to a disease state; and, third, the need to protect patients
against possible adverse drug reactions by identifying
poor metabolizers at the initiation of drug therapy. The
use of genotyping in the identification of poor
metabolizers prior to the initiation of drug therapy is an
appealing emerging opportunity for
pharmacogenomics. Physicians may choose to screen
their patients before administering certain drugs.  
PERSONALIZED MEDICINE AND DRUG
DEVELOPMENT
The basic science of pharmacogenomics is already
contributing substantially to drug research and
development (R&D). The pharmaceutical industry has
embraced pharmacogenomics and the use of
pharmacogenomic strategies has become an integral
component to well over 100 clinical trials. Indeed, a
recent count of the trials employing pharmacogenomic
strategies yielded 144 trials that are currently recruiting
and an additional 97 that are completed (8). 
The drug discovery process has generally been labour-
and-time-intensive, with industry scientists selecting
new molecular entities (NMEs) that correlate with
appropriate targets and testing them through preclinical
and clinical phases to validate safety and efficacy of the
more promising candidates. However, knowledge
garnered from the Human Genome Project coupled with
a novel complement of genomic technologies provides
researchers with a much broader range of targets at
which to aim potential therapeutic interventions. The
wide array of genomic technologies including high-
throughput technologies, global gene expression
analysis, genome-wide functional analyses and gene
expression monitoring allows for the genetic analyses
of numerous NMEs for toxicity and efficacy, thus
streamlining the drug discovery process while
enhancing prospects for better therapies (4).
The identification and screening of candidate genes,
polymorphisms, correlation of polymorphisms with
possible therapeutic targets, prediction of drug response
and clinical outcomes, and selection of therapeutic
dosages on the basis of genotype, are all activities that
fall in the purview of pharmacogenomics (4). Thus, the
field of pharmacogenomics can impact the drug
development process throughout all stages of the R& D
pipeline.
THE PROMISE AND POWER OF
PERSONALIZED MEDICINE
There are several well-known examples of
personalized medicine applications based upon using
pharmacogenomics (table 1). However, clinical
applications of personalized genomic medicine are
occurring at a variable pace, and the following
examples will serve to highlight some of the reasons for
this inconsistency in application. 
Herceptin® and HER-2/neu Testing 
The breast cancer chemotherapeutic trastuzumab
(Herceptin®) is often seen as the "poster child" for
Drug Polymorphic gene
Warfarin 
Phenytoin
Tolbutamide, glipizide
CYP2C9
Flouxetine
Codeine
CYP2D6
5-Flourouracil Dihydropyrimidine dehydrogenase
Antiepileptic drugs MDR1 (or ABCB1)
6-Mercaptopurine
6-thioguanine
Azathioprine
TPMT
b-agonists (e.g. albuterol) b2-adrenergic receptors
b-blockers (e.g. propranolol) Angiotensin-converting enzyme
(ACE)
Losartan Angiotensin IItype I-receptor (AT-1)
Irinotecan  UDP-glucoronosyltransferase 1A1
(UGT1A1)
Abacavir Human leukocyte antigen (HLA)
Sulfonamides
Isoniazid, 
Procainamide
Hydralazine
N-acetyltransferases (NATs)
Imatinib mesylate (Gleevec) BCR/ABL
Herceptin (transtuzumab) Her-2/neu
Thioridazine CYP 2D6
Strattera (atomoxetine) CYP 2D6
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personalized medicine. Indeed, the story of the
development and approval of Herceptin® represents an
interesting case study of personalized medicine. 
Herceptin® is a genetically engineered humanized
monoclonal antibody that was developed after the
discovery of the human epidermal growth factor
receptor-2 protein (HER-2/neu). The discovery that the
human epidermal growth factor receptor-2 (HER-2)
protein on the surface of breast cancer cells is over
expressed in approximately 25-30% of breast cancer
patients led to the development of a therapeutic
antibody that could target HER-2 (9,10). Trastuzumab
was approved by the Food and Drug Administration
(FDA) in 1998 (11). Trastuzumab was initially
approved in combination with paclitaxel for patients
with metastatic breast cancer whose tumors over-
expressed HER-2 and who had not received any
treatment for their disease. Trastuzumab, as a single
agent, is indicated for patients with metastatic breast
cancer whose tumors over-expressed HER-2 and who
had not responded to other chemotherapeutics.
The story of HER-2 testing and Herceptin® illustrate
a fast and successful adoption of a pharmacogenomic
intervention. In its first full year on the U.S. market,
Herceptin's® sales were $188 million (12). Since that
time, the sales of Herceptin® have continued to grow
rapidly. Herceptin® is among the top 20 best-selling
biotech drugs, with sales of $747 Million in 2005 and a
growth rate of 56% between 2004 and 2005 (13). 
Other oncologic drugs that appear to have followed a
similar path through the pipeline and may be considered
examples of personalized medicine include imatinib
mesylate (Gleevac®) and rituximab (Rituxan®). In
patients with Philadelphia chromosome positive chronic
myeloid leukemia (CML), Gleevac® is a protein
tyrosine kinase inhibitor that inhibits the bcr-abl
tyrosine kinase (14,15). Rituxan® is indicated for
CD20-positive, B-cell non-Hodgkin's lymphoma
(16,17).
Genotyping for Warfarin Dosing
More recently, a "real world" application of
personalized medicine has been described that involves
the stratification of the commonly prescribed
anticoagulant warfarin dosing based on variation in the
vitamin K epoxide reductase complex 1 (VKORC1) and
cytochrome P450 2C9 (CYP450 2C9) gene
polymorphisms (18-20). Indeed, the U.S. FDA Clinical
Pharmacology Sub-Committee (CPSC) Advisory
Committee voted to re-label the dosing of warfarin to
take into consideration the new information (21).
Tests for CYP450 drug metabolizing enzymes
A major cause of variability in drug response is due to
mutations in cytochrome P450 (CYP450) drug
metabolizing enzymes (22). These mutations are
relevant to many commonly used drugs such as anti-
depressants and cardiovascular drugs, and the most-
studied enzyme, CYP2D6, is estimated to be a major
contributor to the metabolism of 25% of drugs (23). 
The visibility of CYP450 testing was raised
substantially with the FDA approval of the AmpliChip®
CYP450 test, developed by Roche Molecular
Diagnostics, Inc. Its approval has been called a
"milestone" in personalized medicine (24). The
AmpliChip® tests for genetic mutations in two
common drug metabolizing enzymes (CYP2D6 and
CYP2C19) that are relevant to many drugs, and thus the
test has received widespread attention in both the
industry and lay press. 
Despite widespread interest in the use of AmpliChip®
and similar CYP450 tests, adoption into clinical
practice has been slow. A major challenge to the
adoption of CYP450 tests is the current lack of evidence
about their clinical utility and how to use the tests in
clinical practice. It has been difficult to determine when
testing would be useful for many reasons, including the
multi-factorial nature of drug response, lack of evidence
linking mutations to important clinical outcomes, and
variability not only across but also within drug classes
(25). Furthermore, since a single CYP450 mutation is
unlikely to be responsible for drug response, tests such
as AmpliChip® are not gatekeeper tests that determine
the use or non-use of a drug, such as HER2 testing for
Herceptin®. 
PARADIGM CHANGES IN HEALTH CARE AND
HEALTH CARE SYSTEMS
The examples of current applications described above
illustrate the potential for pharmacogenomic strategies
to improve health care by risk-stratification and more
tailored therapeutic interventions. But they also portend
significant challenges to our health systems, and
highlight the need for significant changes including
infrastructure changes in health care. 
High-Quality, Unified Systematic Databases Are
Essential
The need to match patient genotypes to drug
responsiveness is inherently a complex endeavour and
no clinician can reasonably be expected to achieve this
unaided. This problem underscores the critical lack of
the use of appropriate, efficient and effective
information technology (IT) in health care delivery (26,
27). Thus, one key paradigmatic change that
personalized medicine will bring to the health care
infrastructure is the need to advance existing IT
technologies and develop high quality databases.
However, linking clinical data and genomic data sets is
likely to present a formidable integration challenge. An56 McGill Journal of Medicine 2007
even greater barrier will be the incorporation of
treatment algorithms informed by these data. 
Post-marketing Surveillance
Adverse drug reactions (ADRs) constitute a major
worldwide problem. The promise that the use of
pharmacogenomic strategies might overcome the
serious public health problem of ADRs is one goal of
current research efforts. Pharmacogenomics appears
promising as an approach to drug surveillance in the
post-approval period. However, there remain
considerable technical and regulatory constraints that
need to be resolved (28). 
Economic and Regulatory Considerations
There are many challenges to determining the value of
pharmacogenomic interventions. Many of these
challenges are technical issues, such as a lack of data
that links interventions to health outcomes and costs,
and that provides comparisons to alternative
approaches. Another technical challenge is the need to
evaluate multi-factorial conditions and diagnostic-drug
combinations to assess value. Other challenges emerge
from the policy context. The value of diagnostics is
often harder to measure than the value of drug therapies.
For example, payers may be concerned that the up-front
costs of testing will be higher than the downstream
savings. 
Although numerous observers have discussed the
potential value of personalized medicine and
pharmacogenomics, there is currently little empirical
evidence supporting such claims. To date, there are few
cost-effectiveness analyses of pharmacogenomic
interventions, with inconclusive results as to whether
such interventions are a relatively good value (29).
There are also relatively few mechanisms or incentives
to assess economic value from a societal perspective.
Coverage and reimbursement policies may be
considered the ultimate incentive for industry to bring
products to the market. However, there is currently
much ambiguity about whether pharmacogenomic
interventions are or will be covered, by whom, and at
what rates.
Ethical Challenges
There are also security, ethical and privacy issues to
be resolved (4, 30). Some of these are highlighted in
table 2. 
SUMMARY AND CONCLUSIONS
In this special focus article, I have highlighted some
of the key considerations for better integrating
personalized medicine into clinical practice. 
Using pharmacogenomic strategies in conjunction
with family and clinical histories offers exciting and
promising advances towards personalized medicine and
novel tools to add to the repertoire of clinicians.
However, a number of challenges remain towards fully
realizing the potential of these genomic technologies
and strategies. These challenges will affect the delivery
of health care and health systems at multiple levels
including infrastructure changes, development and
implementation of high quality databases and IT-based
technologies, education of current and future healthcare
professionals, and appropriately resolving ethical and
policy societal concerns. Indeed, it is essential that
ethics and policy develop in tandem with scientific
advances in pharmacogenomics. To do so,
pharmaceutical and biotech companies, diagnostic
companies, researchers, medical educators, information
technology managers, healthcare providers,
laboratories, patient advocates, policy makers and other
stakeholders must all work together to carefully review
the issues at hand and consider their interconnected
implications.
My charge to the current medical students and
residents who will become the future health care leaders
of tomorrow is to become trailblazers by actively
participating in directing research priorities at all phases
of discovery and diffusion, and anticipating what will
be the challenges and opportunities for genomics
research and personalized medicine in order to promote
public health and the common good.
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